TriangleNCT00628251 · MORE INFO
Limitations, agreements, and source contact
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- certain Agreement
- other Details
- No publication of the study results may be made until publication of the results of the multi-centre study or 2 years after study completion, whichever is the sooner
- pi Sponsor Employee
- false
- restriction Type
- OTHER
- restrictive Agreement
- true
- limitations And Caveats
- description
- The AEs reported include all events up to the OS data cut-off. After the PFS data cut-off, AEs were only collected for the olaparib and cross-over groups. The safety profile of these 2 groups at OS was consistent with that at the time of PFS.
- point Of Contact
- ClinicalTrialTransparency@astrazeneca.com
- organization
- AstraZeneca
- phone
- +44 7884 735492
- title
- Paula del Rosario
Complete source fields
- certain Agreement
- other Details
- No publication of the study results may be made until publication of the results of the multi-centre study or 2 years after study completion, whichever is the sooner
- pi Sponsor Employee
- false
- restriction Type
- OTHER
- restrictive Agreement
- true
- limitations And Caveats
- description
- The AEs reported include all events up to the OS data cut-off. After the PFS data cut-off, AEs were only collected for the olaparib and cross-over groups. The safety profile of these 2 groups at OS was consistent with that at the time of PFS.
- point Of Contact
- ClinicalTrialTransparency@astrazeneca.com
- organization
- AstraZeneca
- phone
- +44 7884 735492
- title
- Paula del Rosario
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice